Want to see SIGA full AI Analyst Report?
SIGA Stock Chart & Stats
$3.04
$0.04(1.29%)
At close: 4:00 PM EDT
$3.04
$0.04(1.29%)
Day’s Range― - ―
52-Week Range$2.83 - $8.55
Previous CloseN/A
Volume53.73K
Average Volume (3M)607.51K
Market Cap
$225.61M
Enterprise Value$144.51M
Total Cash (Recent Filing)$117.58M
Total Debt (Recent Filing)$439.40K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield26.49%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding71,849,720
10 Day Avg. Volume588,762
30 Day Avg. Volume607,510
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue2.69
Enterprise Value/Gross Profit4.95
Enterprise Value/Ebitda-29.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$66.31M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetSIGA’s debt-free position and substantial cash reserve provide meaningful financial flexibility. This can support product delivery, program development, and operations through uneven procurement cycles without the added burden of interest expense or refinancing pressure.
Government Execution Track RecordSuccessful completion of the 19C agreement and fulfillment of obligations since 2018 demonstrate established execution capability in U.S. smallpox preparedness. That track record can reinforce SIGA’s credibility with government customers and support its role in future procurement programs.
International Expansion And Pipeline ProgressThe Hikma MENA partnership expands TPOXX’s international commercialization reach, while PEP and pediatric development add potential product and program breadth. Together, these initiatives could diversify future demand beyond existing U.S. procurement activity.
Bears Say
Sharp Deterioration In Operating FundamentalsThe current TTM period shows a material weakening in revenue, margins, profitability, and cash generation after stronger prior years. If this deterioration persists, SIGA may have less internally generated funding for development and greater dependence on future product deliveries.
Lumpy Government-driven RevenueHeavy concentration of first-half product revenue in one quarter illustrates how government procurement timing can make reported results highly uneven. This variability complicates planning, creates delivery-dependent cash flows, and increases the risk of weak results between major orders.
Uncertain U.S. Procurement TimingDelays in securing a new multiyear U.S. procurement contract create uncertainty around the timing and scale of future deliveries. Because U.S. government orders are central to the business model, prolonged delays could extend revenue volatility and weaken near-term visibility.
SIGA Technologies News
SIGA FAQ
What was SIGA Technologies Inc’s price range in the past 12 months?
SIGA Technologies Inc lowest stock price was $2.83 and its highest was $8.54 in the past 12 months.
What is SIGA Technologies Inc’s market cap?
SIGA Technologies Inc’s market cap is $225.61M.
When is SIGA Technologies Inc’s upcoming earnings report date?
SIGA Technologies Inc’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were SIGA Technologies Inc’s earnings last quarter?
SIGA Technologies Inc released its earnings results on Aug 06, 2026. The company reported $0.17 earnings per share for the quarter.
Is SIGA Technologies Inc overvalued?
According to Wall Street analysts SIGA Technologies Inc’s price is currently Overvalued.
Does SIGA Technologies Inc pay dividends?
SIGA Technologies Inc pays a Notavailable dividend of $0.6 which represents an annual dividend yield of 26.49%. See more information on SIGA Technologies Inc dividends here
What is SIGA Technologies Inc’s EPS estimate?
SIGA Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SIGA Technologies Inc have?
SIGA Technologies Inc has 71,849,720 shares outstanding.
What happened to SIGA Technologies Inc’s price movement after its last earnings report?
SIGA Technologies Inc reported an EPS of $0.17 in its last earnings report. Following the earnings report the stock price went down -2.244%.
Which hedge fund is a major shareholder of SIGA Technologies Inc?
Currently, no hedge funds are holding shares in SIGA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SIGA Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
SIGA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 37.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.23%
12-Months-Change
Fundamentals
Return on Equity
-1.53%
Trailing 12-Months
Asset Growth
-25.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SIGA Technologies Inc
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
SIGA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial update driven by a strong Q2: profitable quarter, meaningful product deliveries (including completion of the 19C contract), an improving pipeline trajectory, expanding international partnerships (Hikma for MENA) and a solid balance sheet with $118M cash and no debt. Offsetting these positives are persistent execution risks tied to the timing of a new U.S. multiyear procurement award, quarter-to-quarter revenue volatility due to lumpy government orders, and the inherent complexity of international procurements. Overall, the company appears well-positioned but remains exposed to timing risks in government contracting.View all SIGA earnings summariesTechnical Analysis
China Pharma Holdings
―
Dr Reddy's Laboratories
―
Emergent Biosolutions
―
Viatris
―
Perrigo Company
―
Ownership Overview
1.74% Insiders
12.29% Mutual Funds
0.44% Other Institutional Investors
74.13% Public Companies and
Individual Investors